WO2004082822A3 - Methods for isolating crystalline form i of 5-azacytidine - Google Patents
Methods for isolating crystalline form i of 5-azacytidine Download PDFInfo
- Publication number
- WO2004082822A3 WO2004082822A3 PCT/US2004/007896 US2004007896W WO2004082822A3 WO 2004082822 A3 WO2004082822 A3 WO 2004082822A3 US 2004007896 W US2004007896 W US 2004007896W WO 2004082822 A3 WO2004082822 A3 WO 2004082822A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- azacytidine
- crystalline form
- methods
- isolating crystalline
- isolating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05009969A MXPA05009969A (en) | 2003-03-17 | 2004-03-16 | Methods for isolating crystalline form i of 5-azacytidine. |
SI200432065T SI1608634T1 (en) | 2003-03-17 | 2004-03-16 | Methods for isolating crystalline form i of 5-azacytidine |
AU2004222274A AU2004222274B2 (en) | 2003-03-17 | 2004-03-16 | Methods for isolating crystalline Form I of 5-azacytidine |
PL04721078T PL1608634T3 (en) | 2003-03-17 | 2004-03-16 | Methods for isolating crystalline form i of 5-azacytidine |
JP2006507211A JP4792550B2 (en) | 2003-03-17 | 2004-03-16 | Method for separating 5-azacytidine crystal form I |
ES04721078T ES2425474T3 (en) | 2003-03-17 | 2004-03-16 | Methods for isolating the crystalline form I of 5-azacitidine |
CA002518973A CA2518973A1 (en) | 2003-03-17 | 2004-03-16 | Methods for isolating crystalline form i of 5-azacytidine |
BRPI0408506-0A BRPI0408506A (en) | 2003-03-17 | 2004-03-16 | processes for isolation of crystalline form i from 5-azacytidine |
EP04721078.6A EP1608634B1 (en) | 2003-03-17 | 2004-03-16 | Methods for isolating crystalline form i of 5-azacytidine |
DK04721078.6T DK1608634T3 (en) | 2003-03-17 | 2004-03-16 | PROCEDURES FOR INSULATING CRYSTALLINIC FORM OF 5-AZACYTIDINE |
AU2010241198A AU2010241198B2 (en) | 2003-03-17 | 2010-11-03 | Methods for isolating crystalline Form I of 5-azacytidine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/390,530 US6943249B2 (en) | 2003-03-17 | 2003-03-17 | Methods for isolating crystalline Form I of 5-azacytidine |
US10/390,530 | 2003-03-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004082822A2 WO2004082822A2 (en) | 2004-09-30 |
WO2004082822A3 true WO2004082822A3 (en) | 2005-07-07 |
Family
ID=32987551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/007896 WO2004082822A2 (en) | 2003-03-17 | 2004-03-16 | Methods for isolating crystalline form i of 5-azacytidine |
Country Status (16)
Country | Link |
---|---|
US (5) | US6943249B2 (en) |
EP (3) | EP1608634B1 (en) |
JP (1) | JP4792550B2 (en) |
AU (2) | AU2004222274B2 (en) |
BR (1) | BRPI0408506A (en) |
CA (1) | CA2518973A1 (en) |
CY (2) | CY1114213T1 (en) |
DK (2) | DK2181988T3 (en) |
EC (1) | ECSP056023A (en) |
ES (2) | ES2425474T3 (en) |
HU (1) | HUE028268T2 (en) |
MX (1) | MXPA05009969A (en) |
PL (2) | PL1608634T3 (en) |
PT (2) | PT1608634E (en) |
SI (2) | SI1608634T1 (en) |
WO (1) | WO2004082822A2 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8902490A (en) * | 1989-10-06 | 1991-05-01 | Leonardus Mathijs Marie Nevels | METHOD FOR CLEANING FLUE GASES |
ATE314768T1 (en) * | 2001-10-08 | 2006-01-15 | Cit Alcatel | METHOD FOR DISTRIBUTING LOAD BETWEEN SEVERAL COMMON EQUIPMENT IN A COMMUNICATIONS NETWORK AND NETWORK FOR APPLYING THE METHOD |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
US7038038B2 (en) * | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
US7192781B2 (en) * | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
US7759481B2 (en) * | 2007-01-11 | 2010-07-20 | Ivax Corporation | Solid state forms of 5-azacytidine and processes for preparation thereof |
US20110288042A1 (en) * | 2007-08-02 | 2011-11-24 | Chemagis Ltd. | Stable highly pure azacitidine and preparation methods therefor |
JP2010540556A (en) * | 2007-09-26 | 2010-12-24 | マウント サイナイ スクール オブ メディシン | Azacitidine analogues and uses thereof |
EP2211870A1 (en) * | 2007-11-01 | 2010-08-04 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
DK3782611T3 (en) * | 2008-05-15 | 2022-09-05 | Celgene Corp | ORAL FORMULATIONS OF CYTIDINE ANALOGUES AND METHODS OF USING THEREOF |
WO2010014883A2 (en) | 2008-08-01 | 2010-02-04 | Dr. Reddy's Laboratories Ltd. | Azacitidine process and polymorphs |
KR101660549B1 (en) * | 2008-08-08 | 2016-09-27 | 시노팜 타이완 리미티드 | Process for making azacytosine nucleosides and their derivatives |
EP2424845A4 (en) * | 2009-04-27 | 2014-03-05 | Reddys Lab Ltd Dr | Preparation of decitabine |
US20110042247A1 (en) * | 2009-06-25 | 2011-02-24 | Chandrasekhar Kocherlakota | Formulations of azacitidine and its derivatives |
CN103338753A (en) | 2011-01-31 | 2013-10-02 | 细胞基因公司 | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
AU2012236476A1 (en) * | 2011-03-31 | 2013-05-02 | Celgene International Sarl | Systhesis of 5-azacytidine |
WO2013022872A1 (en) | 2011-08-10 | 2013-02-14 | Celgene Corporation | Gene methylation biomarkers and methods of use thereof |
CA2849708A1 (en) | 2011-09-23 | 2013-03-28 | Celgene Corporation | Romidepsin and 5 - azacitidine for use in treating lymphoma |
WO2013049093A1 (en) | 2011-09-26 | 2013-04-04 | Celgene Corporation | Combination therapy for chemoresistant cancers |
MX357835B (en) | 2011-11-03 | 2018-07-26 | Millennium Pharm Inc | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent. |
WO2013080221A2 (en) * | 2011-12-01 | 2013-06-06 | Hetero Research Foundation | Process for alvimopan |
CN104768532B (en) * | 2012-10-25 | 2017-11-28 | 费森尤斯卡比肿瘤学有限公司 | The pharmaceutical composition of the stabilization of the deoxycytidine of 5 azepine 2 ' |
WO2014076616A2 (en) * | 2012-11-19 | 2014-05-22 | Shilpa Medicare Limited | Formulations of 5-azacytidine |
US9765108B2 (en) | 2012-11-19 | 2017-09-19 | Shilpa Medicare Limited | Formulation of 5-azacytidine |
WO2014160698A1 (en) | 2013-03-26 | 2014-10-02 | Celgene Corporation | SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
CN103450303A (en) * | 2013-09-04 | 2013-12-18 | 重庆泰濠制药有限公司 | Azacitidine crystal form A and azacitidine crystal form B as well as preparation method thereof |
LT3182996T (en) | 2014-08-22 | 2023-03-10 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
US20160095925A1 (en) * | 2014-10-01 | 2016-04-07 | Cadila Healthcare Limited | Stable formulation of azacitidine or salts thereof and their process for preparation |
MD3362066T2 (en) | 2015-10-15 | 2022-08-31 | Les Laboratoires Servier Sas | Combination therapy for treating malignancies |
WO2017066611A1 (en) | 2015-10-15 | 2017-04-20 | Celgene Corporation | Combination therapy for treating malignancies |
WO2018074387A1 (en) * | 2016-10-17 | 2018-04-26 | 第一三共株式会社 | Combination therapy method using mdm2 inhibitor and dna methyltransferase inhibitor |
CN109988207B (en) * | 2017-12-29 | 2022-01-04 | 江苏豪森药业集团有限公司 | Preparation method of azacitidine crystal form |
CN110642901A (en) * | 2019-11-11 | 2020-01-03 | 扬子江药业集团有限公司 | Azacitidine methanolate, preparation method thereof, pharmaceutical composition and application |
WO2022251663A2 (en) * | 2021-05-27 | 2022-12-01 | Emory University | Novel universal anti-rna virus agents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3891623A (en) * | 1971-05-04 | 1975-06-24 | Schering Ag | Process for preparing cytidines |
US6723728B2 (en) * | 2001-03-01 | 2004-04-20 | Gilead Sciences, Inc. | Polymorphic and other crystalline forms cis-FTC |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1050899A (en) * | 1963-12-22 | |||
CH527207A (en) | 1968-05-08 | 1972-08-31 | Ceskoslovenska Akademie Ved | Process for the preparation of 1-glycosyl-5-azacytosines |
CH507969A (en) * | 1968-11-12 | 1971-05-31 | Ceskoslovenska Akademie Ved | Process for the preparation of 1-glycosyl-5-azacytosines |
DE2012888C3 (en) | 1970-03-14 | 1981-04-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Process for the preparation of 5-azapyrimidine nucleosides |
FR2123632A6 (en) | 1971-01-26 | 1972-09-15 | Ceskoslovenska Akademie Ved | Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine |
DE2508312A1 (en) * | 1975-02-24 | 1976-09-02 | Schering Ag | NEW PROCESS FOR THE PRODUCTION OF NUCLEOSIDES |
DE2757365A1 (en) * | 1977-12-20 | 1979-06-21 | Schering Ag | NEW PROCESS FOR THE PRODUCTION OF NUCLEOSIDES |
US5700640A (en) | 1994-09-16 | 1997-12-23 | Basf Aktiengesellschaft | Inducers of gamma globin gene expression and screening assays therefor |
US5539209A (en) | 1994-10-17 | 1996-07-23 | Trojan Technologies Inc. | Method of cleaning fouling materials from a radiation module |
JPH1053576A (en) * | 1996-06-07 | 1998-02-24 | Eisai Co Ltd | Polymorphic crystal of donepezil hydrochloride and its production |
TW513409B (en) | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
WO1998016186A2 (en) | 1996-10-16 | 1998-04-23 | Icn Pharmaceuticals, Inc. | Monocyclic l-nucleosides, analogs and uses thereof |
CA2375601C (en) * | 1999-06-03 | 2008-07-29 | Eisai Co., Ltd. | Carbapenem compound crystals and injection preparations |
WO2001004115A2 (en) * | 1999-07-09 | 2001-01-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel process for synthesis of heteroaryl-substituted urea compounds |
US20020048610A1 (en) | 2000-01-07 | 2002-04-25 | Cima Michael J. | High-throughput formation, identification, and analysis of diverse solid-forms |
IL154718A0 (en) | 2000-09-07 | 2003-10-31 | Kaneka Corp | Methods for crystallization of hydroxycarboxylic acids |
WO2004028454A2 (en) | 2002-09-24 | 2004-04-08 | Koronis Pharmaceuticals, Incorporated | 1, 3, 5-triazines for treatment of viral diseases |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
AU2003286836A1 (en) | 2002-10-31 | 2004-06-07 | Supergen, Inc. | Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
EP1517893A2 (en) * | 2003-02-03 | 2005-03-30 | Teva Pharmaceutical Industries Limited | Process for producing levetiracetam |
US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
US6877855B2 (en) | 2003-07-08 | 2005-04-12 | Dave Ng | Spectacles with peripheral lens support |
EP1667680A4 (en) | 2003-08-29 | 2008-10-08 | Aton Pharma Inc | Combination methods of treating cancer |
US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
US20080057086A1 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
US7759481B2 (en) | 2007-01-11 | 2010-07-20 | Ivax Corporation | Solid state forms of 5-azacytidine and processes for preparation thereof |
EP2114152A1 (en) | 2007-01-25 | 2009-11-11 | Nevada Cancer Institute | Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents |
US20110288042A1 (en) | 2007-08-02 | 2011-11-24 | Chemagis Ltd. | Stable highly pure azacitidine and preparation methods therefor |
EP2048151A1 (en) | 2007-10-10 | 2009-04-15 | Cilag AG | Method for producing nucleosides by direct glycosylation of the nucleoside base |
EP2211870A1 (en) | 2007-11-01 | 2010-08-04 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
DK3782611T3 (en) | 2008-05-15 | 2022-09-05 | Celgene Corp | ORAL FORMULATIONS OF CYTIDINE ANALOGUES AND METHODS OF USING THEREOF |
WO2010014883A2 (en) | 2008-08-01 | 2010-02-04 | Dr. Reddy's Laboratories Ltd. | Azacitidine process and polymorphs |
WO2010017374A1 (en) | 2008-08-06 | 2010-02-11 | Sicor Inc. | Process for preparing azacytidine intermediate |
KR101660549B1 (en) | 2008-08-08 | 2016-09-27 | 시노팜 타이완 리미티드 | Process for making azacytosine nucleosides and their derivatives |
US20110042247A1 (en) | 2009-06-25 | 2011-02-24 | Chandrasekhar Kocherlakota | Formulations of azacitidine and its derivatives |
WO2011014541A1 (en) | 2009-07-30 | 2011-02-03 | Eagle Pharmaceuticals, Inc. | Stable formulations of azacitidine |
IT1399195B1 (en) | 2010-03-30 | 2013-04-11 | Chemi Spa | PROCESS FOR THE SYNTHESIS OF AZACITIDINE AND DECITABINE |
-
2003
- 2003-03-17 US US10/390,530 patent/US6943249B2/en not_active Expired - Lifetime
-
2004
- 2004-03-16 SI SI200432065T patent/SI1608634T1/en unknown
- 2004-03-16 PL PL04721078T patent/PL1608634T3/en unknown
- 2004-03-16 JP JP2006507211A patent/JP4792550B2/en not_active Expired - Lifetime
- 2004-03-16 EP EP04721078.6A patent/EP1608634B1/en not_active Expired - Lifetime
- 2004-03-16 PL PL10151392.7T patent/PL2181988T3/en unknown
- 2004-03-16 WO PCT/US2004/007896 patent/WO2004082822A2/en active Application Filing
- 2004-03-16 EP EP10178178A patent/EP2266965A1/en not_active Withdrawn
- 2004-03-16 HU HUE10151392A patent/HUE028268T2/en unknown
- 2004-03-16 ES ES04721078T patent/ES2425474T3/en not_active Expired - Lifetime
- 2004-03-16 PT PT47210786T patent/PT1608634E/en unknown
- 2004-03-16 BR BRPI0408506-0A patent/BRPI0408506A/en not_active IP Right Cessation
- 2004-03-16 AU AU2004222274A patent/AU2004222274B2/en not_active Expired
- 2004-03-16 PT PT101513927T patent/PT2181988E/en unknown
- 2004-03-16 MX MXPA05009969A patent/MXPA05009969A/en active IP Right Grant
- 2004-03-16 EP EP10151392.7A patent/EP2181988B1/en not_active Revoked
- 2004-03-16 SI SI200432323A patent/SI2181988T1/en unknown
- 2004-03-16 DK DK10151392.7T patent/DK2181988T3/en active
- 2004-03-16 CA CA002518973A patent/CA2518973A1/en not_active Withdrawn
- 2004-03-16 ES ES10151392.7T patent/ES2575535T3/en not_active Expired - Lifetime
- 2004-03-16 DK DK04721078.6T patent/DK1608634T3/en active
-
2005
- 2005-08-05 US US11/198,550 patent/US7700770B2/en not_active Expired - Lifetime
- 2005-09-16 EC EC2005006023A patent/ECSP056023A/en unknown
-
2010
- 2010-03-22 US US12/729,116 patent/US8211862B2/en not_active Expired - Lifetime
- 2010-11-03 AU AU2010241198A patent/AU2010241198B2/en not_active Expired
-
2012
- 2012-06-05 US US13/489,307 patent/US8481715B2/en not_active Expired - Lifetime
-
2013
- 2013-06-07 US US13/913,163 patent/US8975392B2/en not_active Expired - Lifetime
- 2013-08-14 CY CY20131100700T patent/CY1114213T1/en unknown
-
2016
- 2016-05-31 CY CY20161100474T patent/CY1117639T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3891623A (en) * | 1971-05-04 | 1975-06-24 | Schering Ag | Process for preparing cytidines |
US6723728B2 (en) * | 2001-03-01 | 2004-04-20 | Gilead Sciences, Inc. | Polymorphic and other crystalline forms cis-FTC |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004082822A3 (en) | Methods for isolating crystalline form i of 5-azacytidine | |
WO2004082619A3 (en) | Forms of 5-azacytidine | |
MXPA05012025A (en) | Imidazo and thiazolopyridines as jak3 kinase inhibitors. | |
WO2007148185A3 (en) | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors | |
WO2004074244A3 (en) | Pyrimidine compounds | |
MX2007005221A (en) | Ascomycin crystalline forms and preparation thereof. | |
WO2006069363A3 (en) | Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride | |
WO2009146218A3 (en) | Compounds including an anti-inflammatory pharmacore and methods of use | |
WO2007009109A3 (en) | Antiviral compounds | |
WO2008083248A3 (en) | Cyclopamine analogs | |
WO2005085236A3 (en) | Caspase inhibitors and uses thereof | |
WO2006092213A8 (en) | Pyrazolylcarboxanilides | |
MXPA05012026A (en) | Azaindole compounds as kinase inhibitors. | |
WO2004089947A3 (en) | Novel compounds having an antibacterial activity | |
WO2006052568A3 (en) | Tgf-beta inhibitors | |
WO2003095455A3 (en) | Substituted pyrazolopyrimidines | |
WO2004106293A3 (en) | Oxazolyl - and thiazolyl - purine based tricyclic compounds. | |
WO2005021536A3 (en) | Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors | |
WO2005075467A3 (en) | Crystalline forms of zolmitriptan | |
WO2005005389A3 (en) | Malonamide derivatives | |
TW200420541A (en) | Crystalline forms | |
WO2008088779A3 (en) | Solid state forms of 5-azacytidine and processes for preparation thereof | |
WO2004050663A3 (en) | An improved process for the preparation of cefuroxime sodium | |
WO2005028474A3 (en) | Pyrazoloquinoline derivatives as chk-1 inhibitors | |
WO2006031929A3 (en) | Thiazolopyridine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004222274 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2518973 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/009969 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006507211 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004222274 Country of ref document: AU Date of ref document: 20040316 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004222274 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004721078 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004721078 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0408506 Country of ref document: BR |